AbbVie
ABBV
1,605 hedge funds and large institutions have $73.6B invested in AbbVie in 2014 Q4 according to their latest regulatory filings, with 200 funds opening new positions, 546 increasing their positions, 662 reducing their positions, and 83 closing their positions.
141% more first-time investments, than exits
New positions opened: 200 | Existing positions closed: 83
69% more call options, than puts
Call options by funds: $1.15B | Put options by funds: $678M
18% more funds holding in top 10
Funds holding in top 10: 80 → 94 (+14)
7% more funds holding
Funds holding: 1,502 → 1,605 (+103)
1% more capital invested
Capital invested by funds: $72.7B → $73.6B (+$899M)
8.54% less ownership
Funds ownership: 79.06% → 70.51% (-8.5%)
18% less repeat investments, than reductions
Existing positions increased: 546 | Existing positions reduced: 662
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECU
Egerton Capital (UK)
London,
United Kingdom
|
+$246M |
| 2 |
D.E. Shaw & Co
New York
|
+$213M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$186M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$182M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$155M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.98B |
| 2 |
SC
Sculptor Capital
New York
|
-$963M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
-$758M |
| 4 |
PC
Paulson & Co
New York
|
-$751M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$622M |
ABBV Hedge Fund Activity: Q4 2014 in Review
1,605 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2014, worth a combined $73.6B — up 1.2% from $72.7B a quarter earlier.
Buyers outnumbered sellers: 200 funds opened new ABBV positions and 83 closed out — a net gain of 117 holders — while 546 added to existing stakes and 662 trimmed.
The largest buyer was Egerton Capital (UK), opening a new position worth an estimated $246M. The largest seller was Fidelity Investments, cutting an estimated $2.98B.
- 1,605 institutional investors held AbbVie (ABBV) as of Q4 2014, up from 1,502 in Q3 2014.
- Funds reported $73.6B of AbbVie stock for Q4 2014, up 1.2% quarter-over-quarter.
- 200 funds opened new AbbVie positions in Q4 2014 and 83 closed out, a net change of +117 holders.
- The largest AbbVie buyer in Q4 2014 was Egerton Capital (UK), an estimated $246M added.
- The largest AbbVie seller in Q4 2014 was Fidelity Investments, an estimated $2.98B sold.
Based on aggregated 13F filings for Q4 2014.